What treatment can cure my mom’s AATD at 52?

Question

Hello, Doctor,

My 52 year old mother has had intrinsic asthma for nearly fifteen years and was recently found to carry alpha-1 antitrypsin deficiency (AATD) during routine genetic screening. Her pulmonologist has mentioned this combination could be concerning, but has not clearly explained what the actual long term risk looks like for someone in her specific situation. She is a non smoker and has never worked in a dusty or chemical environment. Still, her breathing has been gradually worsening over the last two years despite using her inhalers regularly. Please tell me,

Can intrinsic asthma at 52 in someone with Alpha-1 deficiency actually lead to full COPD development over time?
How aggressively should her lung function be monitored given this particular combination of conditions?
Are there specific treatments or augmentation therapies for Alpha-1 that could meaningfully slow any progression before it becomes irreversible?

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

Your mother has long-standing intrinsic asthma and has now been identified to have Alpha-1 antitrypsin deficiency. This combination does increase the risk of progressive airflow limitation over time, even in a non-smoker. While asthma and chronic obstructive pulmonary disease (COPD) are different conditions, in patients with Alpha-1 deficiency, there can be the development of emphysema leading to a COPD-like picture, especially if lung function shows a gradual decline and becomes less reversible.

The fact that she has never smoked and has no occupational exposure is strongly in her favour and significantly slows the expected progression. However, the recent worsening over the last two years suggests that closer monitoring is now important.

In terms of follow-up, spirometry every 6 months is appropriate in her case to track any early decline in lung function. A baseline High-Resolution Computed Tomography (HRCT) chest is useful to look for early emphysematous changes, particularly in the lower lung zones, and is not required repeatedly unless there is clinical worsening or a drop in spirometry values. Regular clinical assessment of symptoms and inhaler response is equally important.

Treatment should focus first on optimal asthma control with correct inhaler use and adherence. Regarding alpha-1, augmentation therapy is not started based on genetic diagnosis alone. It is considered when there is a confirmed deficiency along with evidence of emphysema and persistent airflow obstruction, particularly if lung function continues to decline despite optimal inhaled therapy. Starting it too early without objective progression is not usually recommended.

In my experience, patients like your mother, especially non-smokers identified early, can remain stable for many years if monitored carefully and managed appropriately. The key is early detection of any decline and timely intervention.

Hope I have addressed all of your queries and concerns.

I hope this information helps you.

Feel free to ask further queries.

Thank you.